[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Univeridad Autonoma de Guadalajara\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100581031","csf-proteomic-characterization-of-glioblastomas-100581031",false,"NCT06845020","CSF Proteomic Characterization of Glioblastomas","The Effects of CSF of Patients with Glioblastomas on the Microglial Immune Profile","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of glioblastoma (histopathological and molecular).\n* Patients who voluntarily accept participation in this study.\n* Patients aged 18 or older.\n\nExclusion Criteria:\n\n* Patients who cannot be followed up at the Regional Hospital 'Dr. Valentin Gomez Farias' ISSSTE.\n* Contamination of the required sample (CSF, serum, tumor).\n* Patients with whom no sampling was obtained or subjects with incomplete background information.\n* Patients who decide to withdraw participation from the study.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to identify proteins that can be found in the cerebrospinal fluid (CSF) of patients with grade IV brain tumors, specifically glioblastomas, and correlate these proteins with progression free survival, overall survival and performance status (functionality). All participants with high probability of glioblastoma will initially be included, final inclusion will be dependent on the definitive histopathological diagnosis of the tumor.\n\nThe main question is:\n\nCan the researchers identify a proteomic profile in CSF from study participants with glioblastoma in association with a longer progression free survival? Participants will undergo the following procedures, that do not deviate from normal standard diagnostic care.\n\n1. Lumbar puncture to obtain CSF.\n2. Blood draw.\n3. Trans-surgical tissue sample of the brain tumor. Additionally participants will be planned for follow up appointments every 3 months following the first 12 months after the surgical tumor resection.",[25,26,27,28,29],"Glioblastoma","Glioblastoma WHO Grade IV","Glioblastoma (GBM)","Glioblastoma Multiforme of the Brain","Glioblastoma, Adult",[25,31,32,33,34,35],"Cerebrospinal fluid","CSF","GBM","Proteomics","Biomarker","NOT_YET_RECRUITING","2025-02-21",{"date":39,"type":40},"2025-02-25","ACTUAL",{"date":42,"type":20},"2025-03-01",{"date":44,"type":20},"2028-03-30",{"name":46,"class":47},"Univeridad Autonoma de Guadalajara","OTHER",""]